ANDA 205319, held by Breckenridge Pharmaceutical. Montelukast Sodium.
As of Nov 21, 2026, ANDA 205319 (Montelukast Sodium), held by Breckenridge Pharmaceutical, was first approved by FDA on Oct 30, 2020, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 30, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Montelukast SodiumEQ 10MG BASE · tablet;oral | Montelukast Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters